Interestingly, while in advanced NSCLC, MTAP loss and CDKN2A/B alteration are reported in up to 13% and 19% of cases [34,35], we found a frequency of 30% and 48%, respectively. This evidence concerns the gene CDKN2A and non-small cell lung carcinoma.